Table 1 Demographic and clinical characteristics of patients with RA and HC
From: Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis
RA (10) | HC (10) | |
|---|---|---|
Age at the time of biopsy (median years, range) | 56 (45–61) | 58 (45–63) |
Gender (n, % of female) | 9 (90%) | 8 (80%) |
Disease duration (median years, range) | 3 (1–5) | NA |
ACPA positivity (n, %) | 10 (100%) | NA |
RF status (n, %) | 10 (100%) | NA |
DAS28 (median, range) | 5.1 (4.8–5.9) | NA |
Low dosage of steroids (n, %) | 8 (80%) | NA |
Methotrexate (n, %) | 10 (100%) | NA |